KhanA, . A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care 2017; 21:234. doi: 10.1186/s13054-017-1823-x10.1186/s13054-017-1823-x)| false
MonteilV, . Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181:905−913.e7. doi: 10.1016/j.cell.2020.04.00410.1016/j.cell.2020.04.004)| false
WysockiJ, . A novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infection in human kidney organoids. J Am Soc Nephrol[published online ahead of print February 1, 2021]. doi: 10.1681/asn.2020101537; https://jasn.asnjournals.org/content/early/2021/01/29/ASN.2020101537)| false
LiuP, et al.. Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int2018; 94:114−125. doi: 10.1016/j.kint.2018.01.029
LiuP, . Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int 2018; 94:114−125. doi: 10.1016/j.kint.2018.01.02910.1016/j.kint.2018.01.029)| false
1 Andrew M. South, MD, MS, is with the Departments of Pediatrics-Section of Nephrology and Surgery-Hypertension and Vascular Research, Division of Public Health Sciences, and Department of Epidemiology and Prevention, Brenner Children’s Hospital, Wake Forest School of Medicine, Winston-Salem, NC. Matthew A. Sparks, MD, FASN, is Assistant Professor of Medicine, Associate Program Director of Nephrology Fellowship, and Director of Medical Student Research in the Department of Medicine, Duke University, and staff physician for the Durham VA Health System, Durham, NC.